

# LAURA SANZ VILLANUEVA

Biologist with Master's degree in Genetics

+61 (0)432124062

[laura.sanz.villanueva@gmail.com](mailto:laura.sanz.villanueva@gmail.com)

<https://www.linkedin.com/in/laura-sanz-villanueva/>

<https://orcid.org/0000-0003-3318-4224>

## EDUCATION

**PhD in Biomedical and Health Sciences (Melbourne Research Scholarship)** – 2025 – University of Melbourne (Australia).

**Master's in Genetics and Evolution with the specialist in Bio-sanitary (8.79/10)** – 2017 – University of Granada and University of Almeria (Spain).

**University Degree in Biology (7.18/10)** – 2016 – Autonomous University of Madrid (Spain).

## PROJECTS

### HGM-EZH2-LF-2021

Analysis of *EZH2* Mutations in Solid and Liquid Biopsy and its Role as Predictive Biomarker for Chemotherapy in Patients with Follicular Lymphoma

### HEM-LINF-CART-2020

Analysis of the Influence of the Genetic Subtype and Molecular Monitoring in Diffuse Large B Cell Lymphoma Patients Treated with CAR T-cell Therapy

### PI-0310-2018

Integrated Analysis of Pharmacologic Properties, Host Factors, Epigenetic Profile and Its Interactions with the Clinic Phenotype and Severity of Drug-Induced Hepatic Injury

### UMA 18-FEDERJA-193

Integrated Mechanistic, Diagnostic and Prognostic Assessment in Hepatotoxicity

## LANGUAGES

**Spanish:** mother tongue

**English:** C1, overall score 190 (CAE: Certificate in Advanced English, 2020)

## EXPERIENCE

**September 2025 – Present. Research assistant at St Vincent's Institute of Medical Research (University of Melbourne) – Melbourne (Australia)**

Investigating the effect of baricitinib in type 1 diabetes patients from the BANDIT trial.

**November 2022 – September 2025. Casual Laboratory Assistant at St Vincent's Institute Biological Isolator Facility.**

Isolation of human islet of Langerhans for transplantation.

**July 2021 – September 2025. PhD Candidate at St Vincent's Institute of Medical Research (University of Melbourne) – Melbourne (Australia)**

Using complementary genomic and transcriptomic approaches to study the effect of baricitinib in type 1 diabetes.

**February 2020 – July 2021. Research Assistant at Gregorio Maranon Health Research Institute (IISGM) – Gregorio Maranon General University Hospital. Department of Hematology (Spain)**

Genetics and clinical hematologic neoplasia and hematopoietic transplantation Research Group.

**January 2018 – July 2019. Research Assistant at IBIMA – University of Malaga – Hospital Universitario Virgen de la Victoria. Department of Pharmacology (Spain)**

Spanish DILI Group (DILI: drug-induced liver injury). SLATIN DILI Network. Pro-Euro-DILI Registry and Clinical trials databases.

**January 2017 – July 2017. Masters Student at Centre Pfizer at University of Granada – Genomic and Oncology Researching of Government of Andalusia (GENyO). Department of Liquid Biopsy (Spain)**

Role of miRNAs as biomarkers in prostate cancer.

**May 2015 – July 2016. Undergrad Student at Center for Molecular Biology "Severo Ochoa" (CBMSO). Department of Development (Spain)**

Generation and analysis of mutations in CG32809 and CG6811 genes in *Drosophila melanogaster* using CRISPR/cas9 and Gal4-UAS.

## PUBLICATIONS

Bastos-Oreiro M, Sanz-Villanueva L, et al. Cell-Free DNA Dynamic Concentration and Other Variables Are Predictors of Early Progression after Chimeric Antigen Receptor T Cell Therapy in Patients with Diffuse Large B Cell Lymphoma. *Transplant Cell Ther* 2023;29:472.e1-472.e4.

Waibel M, Wentworth JM, So M, et al. Baricitinib and  $\beta$ -Cell Function in Patients with New-Onset Type 1 Diabetes. *N Engl J Med* 2023;389:2140–50.

Martínez-Laperche C, Sanz-Villanueva L, et al. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment. *BMC Cancer* 2022;22:1–9.

## HIGHLIGHTED CONGRESSES

2024 60<sup>th</sup> Annual Meeting of the European Association for the Study of Diabetes

2023 59<sup>th</sup> Annual Meeting of the European Association for the Study of Diabetes

2021 16<sup>th</sup> International Conference of Malignant Lymphoma (ICML) Virtual Edition

2021 26<sup>th</sup> European Hematology Association (EHA) Congress

## COURSES

2023 **Advanced Clinical Variant Interpretation.** Melbourne Genomics

2021 **9<sup>th</sup> Molecular Biology in Hematology (CUBIMOL).** Sponsored by AstraZeneca, Bristol MyersSquibb, Janssen Oncology and Novartis.

2019 **1<sup>st</sup> Training Course COST Action 17-112 Pro-Euro DILI Net. Assessment of Drug-Induced-Liver Injury: Key rules and common pitfalls. How to make a clinical narrative.** University of Malaga (Spain)

2018 **Laboratory Animal Science for Scientists Responsible for the Design or Conduct of Animal Experiment.** University of Malaga (Spain)